Firm expands the largest strategic advisory team exclusively dedicated to Health Sciences with four strategic executive hires in three months.
TAMPA, Fla., Oct. 24, 2023 /PRNewswire/ — Crosstree, the global leader in health sciences M&A, is thrilled to announce the appointment of Sandra G. Callahan to the position of chief marketing and growth officer, the first in the firm’s history, and the addition of three new directors. These hires mark a turning point in the firm’s trajectory and further solidify Crosstree’s position as the largest strategic advisory team exclusively dedicated to Health Sciences.
In her new role, Sandra will support the execution of Crosstree’s vision and ambitious growth plans by elevating and enhancing the firm’s brand and deal origination strategy. Sandra’s expertise in executing high-growth business strategies while centered on delivering value to clients, positions Crosstree to achieve its rapid growth targets.
The strategic hire of three new directors, Roger Christopher, Amanda Dydynski, and Ben Garber, will equip the firm to deliver exceptional outcomes to an increasing number of clients in the health sciences market. The unique and impressive experience of the new investment banking directors specifically broadens the scope of the firm’s coverage in the Pharma Services, Diagnostics and Tools, and Healthcare Technology (and technology services) markets.
“Crosstree is experiencing transformational growth,” said Shane Senior, co-founder and managing director, “and we couldn’t be more pleased to add Sandra’s expertise to our executive team to help us achieve our ambitious targets.” Crosstree consistently closes more Pharma Services transactions globally than any other M&A advisor, and the addition of Sandra and three new investment banking directors will further increase this impressive deal flow across all Health Science industries.
Sandra added, “I’m thrilled to be joining such a distinguished firm at an exciting point in their growth story. Crosstree has closed nearly 200 health sciences deals since its inception, and I’m looking forward to helping the team further enhance both deal flow and exceptional client outcomes.”
Crosstree is a global distinguished boutique investment banking firm focused exclusively on the needs of middle-market companies within three subsectors of the health sciences industries: pharmaceutical services and technology, diagnostics and tools, and healthcare technology. Since 2004, Crosstree has advised on more completed transactions in Pharma Services than any other investment bank. The firm provides clients with a full suite of advisory and capital raising services, including buy-and sell-side mergers and acquisitions advisory, private capital raising, and strategic advisory. Crosstree’s narrow industry focus provides clients deep subject matter expertise to middle-market companies and investors, with unparalleled industry insights, well-established strategic relationships across the globe and superior strategic outcomes. From offices in Tampa, Florida, Crosstree has advised clients throughout North America, Europe, India, China, Latin America, and Australia on transactions ranging from $25 million to more than $1 billion. https://www.crosstreecapital.com/
All securities transactions are offered by and conducted through Crosstree Capital Securities, LLC, a broker-dealer registered with the SEC, a member of FINRA (www.finra.org) and SIPC (www.sipc.org), and an affiliate of Crosstree Capital Partners, Inc.